PubRank

G R Bailie

Author PubWeight™ 48.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 2001 2.81
2 Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 1997 2.47
3 Who provides patients with drug information? Br Med J (Clin Res Ed) 1987 2.04
4 Do diabetic patients inject accurate doses of insulin? Diabetes Care 1981 2.02
5 Nonnarcotic analgesics: prevalence and estimated economic impact of toxicities. Ann Pharmacother 1997 1.53
6 Disruptions in drug therapy in long-term dialysis patients who require hospitalization. Am J Health Syst Pharm 1999 1.48
7 Pharmacokinetics of once-daily IP gentamicin in CAPD patients. Perit Dial Int 1997 1.47
8 Disinfection of CAPD bag ports. Perit Dial Int 1989 1.39
9 Absorption interactions with fluoroquinolones. 1995 update. Drug Saf 1995 1.12
10 Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997 1.05
11 Vancomycin, red neck syndrome, and fits. Lancet 1985 0.99
12 Successful treatment of CAPD peritonitis caused by Neisseria cinerea. Perit Dial Int 1994 0.90
13 Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services. J Clin Pharm Ther 1987 0.89
14 Intravenous or intraperitoneal vancomycin for the treatment of continuous ambulatory peritoneal dialysis associated gram-positive peritonitis? Nephron 1987 0.88
15 Knowledge of hemodialysis and CAPD patients about their prescribed medicines. Clin Nephrol 1990 0.87
16 Intermittent intravenous piperacillin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int 2001 0.87
17 Risk factors for inadequate use of pressurized aerosol inhalers. J Clin Pharm Ther 1988 0.87
18 Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1991 0.87
19 Quinolone-cation interactions: a review. DICP 1991 0.87
20 Comparing medication use in two hemodialysis units against national dialysis databases. Am J Health Syst Pharm 2000 0.87
21 Successful treatment of Aeromonas hydrophila peritoneal dialysis-associated peritonitis using intermittent intraperitoneal gentamicin. Clin Nephrol 1995 0.86
22 Intravenous iron products. ANNA J 1999 0.86
23 Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. J Am Soc Nephrol 2000 0.85
24 Pharmacokinetics of intermittent intraperitoneal ceftazidime. Am J Kidney Dis 1999 0.84
25 Stability of iron dextran (DexFerrum) in peritoneal dialysis bags. Perit Dial Int 1999 0.84
26 Dosing adjustment of 10 antimicrobials for patients with renal impairment. Ann Pharmacother 1995 0.84
27 Pharmacists' perceptions of alternative health approaches--a comparison between U.S. and British pharmacists. J Clin Pharm Ther 1990 0.84
28 Stability of amphotericin B-lipid complex (Abelcet) in peritoneal dialysis solutions. Perit Dial Int 2000 0.83
29 Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. Int J Artif Organs 2005 0.83
30 Cyclosporine-associated arthralgia. Clin Nephrol 1990 0.83
31 Massive and extended rebound of serum lithium concentrations following hemodialysis in two chronic overdose cases. Am J Emerg Med 1998 0.82
32 Unsuccessful treatment of CAPD peritonitis caused by Alcaligenes xylosoxidans subsp. denitrificans. Ren Fail 1995 0.81
33 Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. Clin Nephrol 1993 0.81
34 Correlation of intraperitoneal antibiotic pharmacokinetics and peritoneal membrane transport characteristics. Perit Dial Int 2001 0.81
35 Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis 2001 0.81
36 Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int 2001 0.80
37 Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity. Nephrol Dial Transplant 1996 0.79
38 Aminoglycoside therapy. Improving patient response and safety. Postgrad Med 1984 0.79
39 Red-neck syndrome associated with intraperitoneal vancomycin. Clin Pharm 1990 0.79
40 Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. DICP 1991 0.79
41 Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 1990 0.77
42 Bioavailability of bumetanide in grossly oedematous patients. Clin Pharmacokinet 1987 0.77
43 Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999 0.77
44 Intraperitoneal antibiotics effectively treat non-dialysis-related infections. Perit Dial Int 1995 0.77
45 Peritonitis in automated peritoneal dialysis: antibiotic therapy and pharmacokinetics. Perit Dial Int 2001 0.76
46 Trends in clinical indicators of care for adult peritoneal dialysis patients in the United States from 1995 to 1997. ESRD Core Indicators Workgroup. Kidney Int 1999 0.76
47 Treatment of acute carbamazepine poisoning by hemoperfusion. Am J Emerg Med 1996 0.76
48 Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin. Ann Pharmacother 1993 0.76
49 Exfoliative reaction to vancomycin. Br Med J (Clin Res Ed) 1988 0.75
50 Nutritional markers during peritoneal dialysis: data from the 1998 Peritoneal Dialysis Core Indicators Study. Perit Dial Int 2001 0.75
51 Plasma growth hormone (GH) responses to growth hormone releasing factor (hp GRF 1-44) in familial GH deficiency. Acta Paediatr Scand 1987 0.75
52 Comment: pharmacy manpower contrast--U.K. Drug Intell Clin Pharm 1986 0.75
53 Effects of intraperitoneal cefazolin on mesothelial cells in noninfected CAPD patients. Perit Dial Int 2001 0.75
54 Relationship between peritonitis and exit site infections in CAPD. Adv Perit Dial 1992 0.75
55 Limited systemic absorption of intraperitoneal ceftizoxime in a patient with Serratia marcescens peritonitis. Perit Dial Int 1997 0.75
56 Use of pharmacokinetics to determine the duration of dialysis in management of methanol poisoning. Am J Emerg Med 1998 0.75
57 Cost/benefit analysis of aminoglycoside use without a kinetic dosing service. Drug Intell Clin Pharm 1988 0.75
58 Counseling patients with chronic obstructive lung disease in the use of bronchodilator aerosols. Drug Intell Clin Pharm 1982 0.75
59 Nitroglycerin. Minn Med 1982 0.75
60 Severe accidental dapsone overdose. Am J Emerg Med 1995 0.75
61 Imipenem/cilastatin efficacy evaluated. Drug Intell Clin Pharm 1985 0.75
62 Turbid dialysate effluent and bacterial peritonitis. Clin Nephrol 1991 0.75
63 Possible ganciclovir-induced hepatotoxicity in patients with AIDS. Clin Pharm 1992 0.75
64 Interleukin, endotoxin, and tumor necrosis factor in CAPD dialysate. Perit Dial Int 1995 0.75
65 Trainees' activities and experiences after a clinical pharmacy dialysis traineeship. Am J Health Syst Pharm 1999 0.75
66 Acute renal failure and hyperkalemia associated with triamterene and indomethacin. Vet Hum Toxicol 1986 0.75
67 Effectiveness of theophylline monitoring by the use of serum assays. J Clin Pharm Ther 1988 0.75
68 Patient knowledge of cardio-respiratory drugs. J Clin Pharm Ther 1988 0.75
69 Superior vena cava syndrome from central venous hemodialysis. Clin Nephrol 1994 0.75
70 Stability of erythromycin lactobionate in peritoneal dialysate solutions. Perit Dial Int 1994 0.75
71 Another view of calcium and extrapyramidal side effects. Am J Psychiatry 1983 0.75
72 Propranolol-use in the elderly. Minn Med 1982 0.75
73 Flupenthixol poisoning in a child. Drug Intell Clin Pharm 1981 0.75
74 Drug administration audit. J Clin Hosp Pharm 1981 0.75
75 Timeliness of medication administration in hemodialysis inpatients: drug use evaluation. Hosp Pharm 1993 0.75
76 Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients. Ren Fail 1997 0.75
77 1996 Peritoneal Dialysis Core Indicators Study: report on nutritional indicators. Perit Dial Int 1999 0.75
78 Surreptitious use of antimicrobial agents by CAPD patients. Perit Dial Int 1993 0.75
79 Central nervous system stimulation from isoniazid therapy. Vet Hum Toxicol 1983 0.75
80 Stability of ciprofloxacin injection in peritoneal dialysis solutions. Am J Hosp Pharm 1994 0.75
81 Renal transplant patients' knowledge concerning cyclosporine treatment. Clin Nephrol 1991 0.75
82 Erythropoietin in continuous ambulatory peritoneal dialysis: experience with subcutaneous administration. Perit Dial Int 1992 0.75
83 Moxalactam-induced hypoprothrombinemia with intrahepatic bleeding. Minn Med 1984 0.75
84 Development of an immunoassay for monitoring the levels of ciprofloxacin in patient samples. J Immunoassay 1998 0.75
85 Disposition of intrathecal vancomycin. Drug Intell Clin Pharm 1988 0.75
86 Empiric initial therapy and dose of vancomycin. Perit Dial Int 2001 0.75
87 Bilateral renal cortical necrosis associated with cefuroxime axetil. Clin Nephrol 1998 0.75
88 Unusual treatment response of a severe dystonia to diphenhydramine. Ann Emerg Med 1987 0.75
89 Successful management of steroid-resistant nephrotic syndrome using ibuprofen. Clin Nephrol 1997 0.75
90 Intravenous iron products. Nephrol Nurs J 2000 0.75
91 Variability in creatinine clearance (CCR) and KT/V due to different methods of calculating volume and CCR. Perit Dial Int 1997 0.75
92 Cost-effectiveness of gentamicin vs tobramycin. Pharmacoeconomics 1993 0.75
93 Failure of intraarticular ceftazidime in a patient with Pseudomonas aeruginosa septic arthritis. Drug Intell Clin Pharm 1988 0.75
94 Chemical peritonitis associated with intraperitoneal vancomycin. DICP 1991 0.75
95 Correlation of whole blood activated partial thromboplastin time and plasma activated partial thromboplastin time in haemodialysis patients. Nephrol Dial Transplant 1996 0.75
96 Simplified approach to calculation of V, G, and nPCR for monitoring hemodialysis patients. Ren Fail 1994 0.75
97 Low prevalence of vancomycin-resistant Enterococcus in dialysis outpatients with a history of vancomycin use. Perit Dial Int 1997 0.75
98 The effect of temperature and glucose concentration on the growth of microorganisms commonly associated with CAPD peritonitis. Perit Dial Int 1995 0.75
99 Effect of intermittent hemodialysis on nondepolarizing skeletal muscle relaxants. Ann Pharmacother 1997 0.75
100 Profound hypotension following sublingual nitroglycerin. Vet Hum Toxicol 1983 0.75
101 Stability of deferoxamine peritoneal dialysate solutions. Perit Dial Int 1994 0.75
102 Stability of ofloxacin in peritoneal dialysis solutions. Perit Dial Int 1995 0.75